T. Rowe Price Investment Management Inc. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)

T. Rowe Price Investment Management Inc. grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 474.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 159,057 shares of the biotechnology company's stock after purchasing an additional 131,347 shares during the quarter. T. Rowe Price Investment Management Inc. owned approximately 0.28% of Repligen worth $22,895,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in RGEN. Pinebridge Investments L.P. grew its stake in Repligen by 42.7% during the 4th quarter. Pinebridge Investments L.P. now owns 18,110 shares of the biotechnology company's stock worth $2,607,000 after buying an additional 5,417 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Repligen by 12.1% in the 4th quarter. Stifel Financial Corp now owns 4,939 shares of the biotechnology company's stock valued at $711,000 after acquiring an additional 535 shares during the period. Tower Research Capital LLC TRC boosted its stake in Repligen by 89.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,718 shares of the biotechnology company's stock worth $967,000 after purchasing an additional 3,167 shares during the period. Finally, MetLife Investment Management LLC grew its position in Repligen by 8.9% during the 4th quarter. MetLife Investment Management LLC now owns 29,774 shares of the biotechnology company's stock worth $4,286,000 after purchasing an additional 2,428 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Royal Bank of Canada boosted their target price on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday, February 21st. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Finally, StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Thursday, April 17th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $176.82.

Repligen Stock Down 0.3 %

Repligen stock opened at $144.75 on Friday. The firm has a market capitalization of $8.13 billion, a price-to-earnings ratio of -283.82, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The stock's fifty day moving average is $139.80 and its two-hundred day moving average is $145.86.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.